Merck & Co., Inc. (NYSE:MRK) reported Tuesday promising results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir, a product to treat the chronic hepatitis C virus genotype 1 in treatment-naive and previously-treated patients.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Merck & Co., Inc.'s (NYSE:MRK) cholesterol drug Vytorin was successful in meeting the primary endpoint of lowering the risks of second heart attacks in patients already undergoing an aggressive treatment, results from a study of the drug show.
Merck & Co., Inc. (NYSE: MRK) stock participated in the market's recent upside like most other U.S. equity issues. However, unlike some that broke out to new highs, Merck shares seem to have "hit the wall" in terms of upside momentum at just above $60.
NewLink Genetics Corp (NASDAQ:NLNK) and Merck & Co., Inc. (NYSE:MRK) are rumored to have come to the table for talks to research possible ways to increase the production of NewLink's experimental Ebola vaccine.